Drug Repurposing for Cocaine Use Disorder (CUD) Using a Combined Strategy of Artificial Intelligence (AI)-Based Prediction and Retrospective Clinical Corroboration

An estimated 5.5 million people aged 12 or older were cocaine users and 977,000 people had a cocaine use disorder (CUD). Currently there are no medications approved to treat CUD. Identifying novel pharmacotherapies for CUD, while a priority, has been challenged by the lack of interest from the pharmaceutical industry and by lengthy traditional drug development processes. Thus, research to repurposing existing drugs may accelerate findings of anti-CUD medications. The goal for this study is to identify and evaluate potential anti-CUD drugs by developing artificial intelligence (AI)-powered drug discovery technologies. The output of this project will be a list of promising anti-CUD candidates that may help expeditiously translate into clinical trials to benefit CUD patients.

CTN Protocol ID: 
CTN-0114
Status: 
Development

Principal Investigator(s)

Rong Xu, Ph.D.

Associate Professor
Case Western Reserve University
Epidemiology and Biostatistics

2103 Cornell Road
Cleveland, OH 44106
United States

Theresa Winhusen, Ph.D.

Professor of Psychiatry and Behavioral Neuroscience, Director of Addiction Sciences Division
University of Cincinnati
Addiction Sciences Division

3131 Harvey Avenue, Suite 104
Cincinnati, OH 45229-3006
United States